Somapacitan-beco: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

30 April 2025

  • curprev 08:5308:53, 30 April 2025 Alara E. Dagsali talk contribs 32,450 bytes +32,450 Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=somapacitan-beco |aOrAn=a |drugClass=binds to the growth hormone receptor and induces intracellular signalling to up-regulate insulin-like growth factor I (IGF-1) |indicationType=treatment |indication=SOGROYA is indicated for the: *Treatment of pediatric patients aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone (GH). *Repla..."
Retrieved from "https://www.wikidoc.org/index.php/Somapacitan-beco"